During the past decade, Inje University Busan Paik Hospital conducted 149 clinical trials. In the 10-year time frame, 149 clinical trials started and 33 clinical trials were completed, i.e. on average, 22.1% percent of trials that started reached the finish line to date. In the past 5 years, 57 clinical trials started and 23 clinical trials were completed. i.e. 40.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Inje University Busan Paik Hospital" #1 sponsor was "Seung-Jung Park" with 20 trials, followed by "Boehringer Ingelheim" with 12 trials sponsored, "Chong Kun Dang Pharmaceutical" with 9 trials sponsored, "HK inno.N Corporation" with 9 trials sponsored and "Hoffmann-La Roche" with 9 trials sponsored. Other sponsors include 163 different institutions and companies that sponsored additional 97 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Inje University Busan Paik Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 24 trials as a collaborator, "Eli Lilly and Company" with 8 trials as a collaborator, "Inje University" with 6 trials as a collaborator, "Severance Hospital" with 5 trials as a collaborator and "Abbott" with 4 trials as a collaborator. Other collaborators include 84 different institutions and companies that were collaborators in the rest 77 trials.

According to Clinical.Site data, the most researched conditions in "Inje University Busan Paik Hospital" are "Coronary Artery Disease" (25 trials), "Healthy" (19 trials), "Hypertension" (7 trials), "Hepatitis B" (6 trials) and "Multiple Myeloma" (6 trials). Many other conditions were trialed in "Inje University Busan Paik Hospital" in a lesser frequency.

Most popular intervention types in "Inje University Busan Paik Hospital" are "Drug" (162 trials), "Device" (27 trials), "Procedure" (11 trials), "Biological" (8 trials) and "Other" (8 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Rituximab" (5 trials), "Cypher" (4 trials), "Bendamustine" (3 trials) and "Fimasartan" (3 trials). Other intervention names were less common.

The vast majority of trials in "Inje University Busan Paik Hospital" are 195 trials for "All" genders, 27 trials for "Male" genders and 5 trials for "Female" genders.

Currently, there are 62 active trials in "Inje University Busan Paik Hospital". 1 are not yet recruiting, 43 are recruiting, 17 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 116 completed trials in Inje University Busan Paik Hospital, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in Inje University Busan Paik Hospital, 42 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 37 trials, and there were also 12 trials that are defined as “Not Applicable".